cimb-logo

Journal Browser

Journal Browser

Epithelial Cancers: Molecular Mechanisms, Diagnostic Innovations, and Therapeutic Advances

A special issue of Current Issues in Molecular Biology (ISSN 1467-3045). This special issue belongs to the section "Molecular Medicine".

Deadline for manuscript submissions: 28 February 2025 | Viewed by 388

Special Issue Editor


E-Mail Website
Guest Editor
Department of Physiology, “Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania
Interests: physiology; inflammation; carcinogenesis; medical imaging; transplantation; molecular signaling; MR spectroscopy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear colleagues,

Epithelial cancers originate from the epithelial cells lining organs and tissues and constitute a significant portion of human malignancies. This special issue aims to focus into the intricate molecular processes underlying the development and progression of epithelial cancers, potential interferences and common pathways, as well as specific mechanisms and particularities. We invite original articles, reviews, and other types of papers that explore molecular mechanisms, diagnostic innovations, therapeutic advances, as well as new data on tumor resistance and recurrence, potential pitfalls in the management of these patients, and translational research that bridges the gap between fundamental and clinical research with application in clinical innovation. By encompassing a wide range of topics from molecular biology to clinical practice, our special issue aims to provide a platform for current advancements and future directions in the field of epithelial cancers. We encourage contributions that offer new insights, propose innovative approaches, highlight the translational potential, and overall aim to improve patient outcomes in the context of this type of malignancy.

Dr. Cristian Scheau
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Issues in Molecular Biology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • epithelial cancers
  • molecular mechanisms
  • genetic alterations
  • epigenetics
  • tumor microenvironment
  • epithelial-mesenchymal transition
  • biomarkers
  • liquid biopsy
  • imaging technologies
  • targeted therapies
  • immunotherapies
  • personalized medicine
  • treatment resistance
  • cancer recurrence
  • translational research

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

39 pages, 707 KiB  
Review
Agonists, Antagonists and Receptors of Somatostatin: Pathophysiological and Therapeutical Implications in Neoplasias
by Argyrios Periferakis, Georgios Tsigas, Aristodemos-Theodoros Periferakis, Carla Mihaela Tone, Daria Alexandra Hemes, Konstantinos Periferakis, Lamprini Troumpata, Ioana Anca Badarau, Cristian Scheau, Ana Caruntu, Ilinca Savulescu-Fiedler, Constantin Caruntu and Andreea-Elena Scheau
Curr. Issues Mol. Biol. 2024, 46(9), 9721-9759; https://doi.org/10.3390/cimb46090578 - 2 Sep 2024
Viewed by 193
Abstract
Somatostatin is a peptide that plays a variety of roles such as neurotransmitter and endocrine regulator; its actions as a cell regulator in various tissues of the human body are represented mainly by inhibitory effects, and it shows potent activity despite its physiological [...] Read more.
Somatostatin is a peptide that plays a variety of roles such as neurotransmitter and endocrine regulator; its actions as a cell regulator in various tissues of the human body are represented mainly by inhibitory effects, and it shows potent activity despite its physiological low concentrations. Somatostatin binds to specific receptors, called somatostatin receptors (SSTRs), which have different tissue distributions and associated signaling pathways. The expression of SSTRs can be altered in various conditions, including tumors; therefore, they can be used as biomarkers for cancer cell susceptibility to certain pharmacological agents and can provide prognostic information regarding disease evolution. Moreover, based on the affinity of somatostatin analogs for the different types of SSTRs, the therapeutic range includes conditions such as tumors, acromegaly, post-prandial hypotension, hyperinsulinism, and many more. On the other hand, a number of somatostatin antagonists may prove useful in certain medical settings, based on their differential affinity for SSTRs. The aim of this review is to present in detail the principal characteristics of all five SSTRs and to provide an overview of the associated therapeutic potential in neoplasias. Full article
Back to TopTop